Structure (Structure)
Potassium Citrate Tablet, Extended Release
Product Images NDC 72162-2122
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Potassium Citrate (NDC 72162-2122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Table 1. (Table 1.)
Table 1 presents the effect of Potassium Citrate on patients with Calcium Oxalate Nephrolithiasis. The table shows the number of stones formed per year for different groups of patients at baseline and during treatment. It also indicates the remission rate and the percentage of patients showing any decrease in stone formation. The groups are labeled as Group I, Group II, Group III, and Group IV, with varying sample sizes. The baseline values for stone formation range from 1230 to 4.3, while the values during treatment range from 0.913 to 0.062. The remission rates for the different groups range from 58% to 94%, and the percentage of patients showing any decrease in stone formation ranges from 95% to 100%. "Remission" is defined as the percentage of patients who remained free of newly formed stones during treatment.*
Label (Lbl721622122)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
